London: AstraZeneca The European Union’s drug regulator has accepted a proposal, it said on Monday. Market Authorization Application For this Investigational COVID-19 prevention drug, SepavibartFor quick assessment.

The presentation was based on positive data from late-stage trials showing the drug reduced the risk of infection in immunocompromised patients.

“The EMA”The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has granted accelerated assessment to cipavibart as it is considered to be of major interest for public health and therapeutic innovation,” the Anglo-Swedish drugmaker said.

The aim of the accelerated assessment is to speed up the EMA’s review of a market authorisation application.

AstraZeneca acquired Cipavibart from RQ Bio in May 2022.

The drugmaker earlier this year withdrew its Covid-19 vaccine, one of the first and most widely used vaccines since the pandemic began, due to a “surplus of available updated vaccines”.

(Reporting by Yadrisa Shabong in Bengaluru; Editing by Sonia Cheema)